Inactive Instrument

Analyst Reco. Chinook Therapeutics, Inc.

Equities

KDNY

US16961L1061

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target	23-08-08	MT
Wells Fargo Downgrades Chinook Therapeutics to Equalweight From Overweight, Adjusts Price Target to $40 From $30	23-08-01	MT
ANALYST RECOMMENDATIONS : Meta, Thermo Fisher, Union Pacific, Domino's Pizza...	23-08-01
Evercore ISI Downgrades Chinook Therapeutics to In Line From Outperform, Price Target is $40	23-06-14	MT
Stifel Downgrades Chinook Therapeutics to Hold From Buy, Adjusts Price Target to $41 From $43	23-06-13	MT
HC Wainwright Downgrades Chinook Therapeutics to Neutral From Buy, Price Target is $40	23-06-13	MT
SVB Securities Downgrades Chinook Therapeutics to Market Perform From Outperform, Lowers PT to $40 From $44	23-06-13	MT
Guggenheim Downgrades Chinook Therapeutics to Neutral From Buy, Adjusts Price Target to $40 From $35	23-06-12	MT
Bloom Burton Downgrades Chinook Therapeutics to Hold From Buy, Cuts Price Target to $47 From $51	23-06-12	MT
William Blair Downgrades Chinook Therapeutics to Market Perform From Outperform	23-06-12	MT
Cantor Fitzgerald Downgrades Chinook Therapeutics to Neutral From Overweight, Adjusts Price Target to $40 From $33	23-06-12	MT
Wedbush Adjusts Price Target on Chinook Therapeutics to $42 From $36, Maintains Outperform Rating	23-06-12	MT
Traders Cautious Ahead of Fed Rate Decision, Inflation Numbers as US Equity Futures Waver Pre-Bell	23-06-12	MT
Inflation Data, Fed Rate Decision Anticipation Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Monday	23-06-12	MT
North American Morning Briefing : Rate Decisions, Inflation Data Headline a Busy Week	23-06-12	DJ
European Midday Briefing : Positive Start to Busy Week Ahead as Rate Decisions Loom	23-06-12	DJ
Guggenheim Adjusts Price Target on Chinook Therapeutics to $35 From $43, Maintains Buy Rating	23-05-02	MT
Piper Sandler Starts Chinook Therapeutics at Overweight With $41 Price Target	23-03-06	MT
Guggenheim Initiates Chinook Therapeutics at Buy With $43 Price Target	23-03-01	MT
Oppenheimer Adjusts Chinook Therapeutics Price Target to $34 From $33, Maintains Outperform Rating	23-02-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Chinook Therapeutics, Inc.

Equities

KDNY

US16961L1061

Analyst Reco.

Filters